Simon Ekman1,2, Frank Griesinger3, Paul Baas4, David Chao5, Christos Chouaid6, John C O'Donnell7, John R Penrod7, Melinda Daumont8, Laure Lacoin8, Alexia McKenney9, Masha Khovratovich9, Robin Ej Munro9, Isabelle Durand-Zaleski10, Søren Paaske Johnsen11. 1. Department of Oncology, Karolinska University Hospital, Stockholm, Sweden. 2. Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. 3. Department of Haematology & Oncology, University Department Internal Medicine-Oncology, Pius-Hospital, Medical Campus University of Oldenburg, Oldenburg, Germany. 4. Department of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. 5. Department of Oncology, Royal Free Hospital, London, UK. 6. Pneumology Unit, Centre Hospitalier Intercommunal de Créteil, Créteil, France. 7. Worldwide Health Economics & Outcomes Research, Bristol-Myers Squibb, Princeton, NJ, USA. 8. Worldwide Health Economics & Outcomes Research, Bristol-Myers Squibb, Braine-l'Alleud, Belgium. 9. Real-World & Analytics Solutions, IQVIA, London, UK. 10. URC Eco IdF, Unité de Recherche Clinique en Économie de la Santé d'Ile de France, AP-HP Paris, Paris, France. 11. Danish Center for Clinical Health Services Research, Aalborg University, Aalborg, Denmark.
Abstract
Aim: To describe I-O Optimise, a multinational program providing real-world insights into lung cancer management. Materials & methods: Real-world data source selection for I-O Optimise followed a structured approach focused on population coverage, key variable capture, continuous/consistent data availability, record duration and data latency, and database expertise. Results: As of 31 October 2018, seven real-world data sources were included in I-O Optimise, providing data on characteristics, treatment patterns and clinical outcomes from more than 45,000 patients/year with non-small-cell lung cancer, small-cell lung cancer and mesothelioma across Denmark, Norway, Portugal, Spain, Sweden and the UK. Conclusion: The ongoing I-O Optimise initiative has the potential to provide a broad, robust and dynamic research platform to continually address numerous research objectives in the lung cancer arena.
Aim: To describe I-O Optimise, a multinational program providing real-world insights into lung cancer management. Materials & methods: Real-world data source selection for I-O Optimise followed a structured approach focused on population coverage, key variable capture, continuous/consistent data availability, record duration and data latency, and database expertise. Results: As of 31 October 2018, seven real-world data sources were included in I-O Optimise, providing data on characteristics, treatment patterns and clinical outcomes from more than 45,000 patients/year with non-small-cell lung cancer, small-cell lung cancer and mesothelioma across Denmark, Norway, Portugal, Spain, Sweden and the UK. Conclusion: The ongoing I-O Optimise initiative has the potential to provide a broad, robust and dynamic research platform to continually address numerous research objectives in the lung cancer arena.
Authors: Ilkka Helanterä; Jon Snyder; Anders Åsberg; Josep Maria Cruzado; Samira Bell; Christophe Legendre; Hélio Tedesco-Silva; Giovanna Tedesco Barcelos; Yvonne Geissbühler; Luis Prieto; Jennifer B Christian; Erik Scalfaro; Nancy A Dreyer Journal: Transpl Int Date: 2022-05-03 Impact factor: 3.842
Authors: Marta Soares; Luís Antunes; Patrícia Redondo; Marina Borges; Ruben Hermans; Dony Patel; Fiona Grimson; Robin Munro; Carlos Chaib; Laure Lacoin; Melinda Daumont; John R Penrod; John C O'Donnell; Maria José Bento; Francisco Rocha Gonçalves Journal: Lung Cancer Manag Date: 2021-02-19
Authors: Michael Snee; Sue Cheeseman; Matthew Thompson; Majid Riaz; Will Sopwith; Laure Lacoin; Carlos Chaib; Melinda Manley Daumont; John R Penrod; John C O'Donnell; Geoff Hall Journal: BMJ Open Date: 2021-05-03 Impact factor: 2.692
Authors: Simon Ekman; Pia Horvat; Mats Rosenlund; Anne Mette Kejs; Dony Patel; Ariadna Juarez-Garcia; Laure Lacoin; Melinda J Daumont; John R Penrod; Odd Terje Brustugun; Jens Benn Sørensen Journal: JTO Clin Res Rep Date: 2021-03-24
Authors: Robert Carroll; Margherita Bortolini; Alan Calleja; Robin Munro; Shiying Kong; Melinda J Daumont; John R Penrod; Khalid Lakhdari; Laure Lacoin; Winson Y Cheung Journal: BMC Cancer Date: 2022-03-10 Impact factor: 4.430
Authors: Marta Soares; Luís Antunes; Patrícia Redondo; Marina Borges; Fiona Grimson; Ruben Hermans; Carlos Chaib; Laure Lacoin; Ariadna Juarez-Garcia; Melinda J Daumont; John R Penrod; Maria José Bento; Francisco Rocha Gonçalves Journal: Eur J Cancer Care (Engl) Date: 2021-07-20 Impact factor: 2.328